A narrative literature review reveals improved cure rates in advanced-stage pediatric classic Hodgkin lymphoma, highlighting toxicity and quality of life challenges.
Recent trials introducing novel immunotherapy into the treatment of advanced-stage pediatric classic Hodgkin lymphoma (cHL) suggest that cure rates will exceed 90%. Consequently, more than ever there is a need to minimize the toxicity of treatment and ensure that survivors experience a quality of life unimpaired by late effects. We performed a structured literature review to analyze frontline trials of advanced pediatric cHL, the impact of toxicity of treatments and on health-related quality of life. A total of 6 clinical trials were included, 4 randomized phase 3 trials, 1 non-randomized phase 3 trial and 1 phase 2 trial. One longitudinal study and 5 retrospective registry-based studies were included in the health-related quality of life review. The use of novel systemic treatments has significantly improved outcomes in advanced- pediatric cHL. However, new challenges arise to better understand quality of life outcomes among survivors, and to make new drugs more widely accessible.
No takes yet. Share an insight, caveat, or question.
Shariff et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: